Prediabetes

Welldoc Named “Best Overall Digital Health Company” for Second Consecutive Year in the 8th Annual MedTech Breakthrough Awards Program

Retrieved on: 
星期四, 五月 9, 2024
Technology, FDA, Clinical Trials, Health Technology, Cardiology, Biotechnology, Health, Pharmaceutical, Artificial Intelligence, Medtech, Diabetes, EHR, Partnership, Electronic health record, Privacy, Medical device, Digital health, Telehealth, Hypertension, Prediabetes, Heart failure

Welldoc ®, a leading digital health company specializing in cardiometabolic health, today announced that it has been selected as winner of the “Best Overall Digital Health Company” award for the second consecutive year in the 8th annual MedTech Breakthrough Awards.

Key Points: 
  • Welldoc ®, a leading digital health company specializing in cardiometabolic health, today announced that it has been selected as winner of the “Best Overall Digital Health Company” award for the second consecutive year in the 8th annual MedTech Breakthrough Awards.
  • The awards program is conducted by MedTech Breakthrough , an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market.
  • This is the third year that MedTech Breakthrough has recognized Welldoc for its leadership and innovation in the digital health industry.
  • “We’re thrilled to recognize Welldoc as our ‘Best Overall Digital Health Company’ for 2024.”

Valbiotis publishes its annual accounts 2023

Retrieved on: 
星期五, 五月 3, 2024
FDA, Sales management, Partnership, Hypercholesterolemia, Sleep, INSIGHT, Prevalence, Insulin resistance, Inflammation, DSM-IV codes, Food, Communication, Cholecalciferol, Executive Committee, Pharmacist, Pharmacy, Volunteering, INAF, Phase, Practitioner, Incretin, EFSA, Safety, Omega-3 fatty acid, Agonal respiration, Human, LDL, Marketing, Prediabetes, NAFLD, Endocrine gland, NDI, Food and Drug Administration, Meal, Commercial, Dietary supplement, Blood pressure, Patient, Statutory auditor, Metabolism, Hypertension, Cardiovascular disease, Bank statement, Pharmaceutical industry

Sébastien PELTIER, Chairman of the Executive Committee and Co-Founder of Valbiotis, comments: ‘’2023 was one of Valbiotis' most productive years since the Company was founded just ten years ago.

Key Points: 
  • Sébastien PELTIER, Chairman of the Executive Committee and Co-Founder of Valbiotis, comments: ‘’2023 was one of Valbiotis' most productive years since the Company was founded just ten years ago.
  • By accelerating its structuring, Valbiotis also laid the foundations for 2024, which promises to be particularly fruitful.
  • The Company's 2023 financial statements, drawn up in accordance with IFRS, were approved by the Board of Directors on April 23, 2024.
  • They have been audited by the Statutory Auditor and are available on the Valbiotis website: www.valbiotis.com/en (investors section).

Supergut, the Leader in GLP-1 Functional Foods, Accelerates Its Unprecedented Retail Expansion With Newest Partner, GNC

Retrieved on: 
星期一, 四月 29, 2024
General Health, Food, Beverage, Health, Retail, Fitness & Nutrition, Brain, Malnutrition, Digestion, Walmart, GNC, Bristol Farms, Nausea, Overweight, Diabetes, Insurance, Weight loss, Partnership, GLP-1, Atrophy, Prescription, Obesity, Food industry, Exercise, Science, Vomiting, Starch, Diarrhea, Metabolism, Constipation, Multimedia, Cardiovascular disease, Prediabetes, Immunity, Sleep, Injection, Dietary supplement

The partnership, which includes both in-store and online sales, accelerates Supergut’s unprecedented retail expansion over the past quarter.

Key Points: 
  • The partnership, which includes both in-store and online sales, accelerates Supergut’s unprecedented retail expansion over the past quarter.
  • In addition to this retail explosion, Supergut remains available on Supergut.com and Amazon .
  • “We’re excited to partner with GNC, which shares our values of scientific validation and customer education.
  • Approximately five million Americans take these drugs now, and up to 70 million Americans may use a GLP-1 by 2028 .

Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes

Retrieved on: 
星期四, 四月 25, 2024
School, JMIR, University, University Challenge 2013–14, Prediabetes, Public health, Blood pressure, Dario, Overweight, BMI, Diabetes, Partnership, Empowerment, Research, A1C, Obesity, Blood, Type 2 diabetes, Medicine, Journal, Medical device

NEW YORK, April 25, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR) demonstrating a clinically significant reduction in blood glucose levels for members using Dario to manage weight alongside diabetes.

Key Points: 
  • Dario's cardiometabolic solution helps people manage related cardiometabolic health needs, including diabetes, pre-diabetes, blood pressure, weight and support for people taking a GLP-1, with a single integrated and highly personalized experience.
  • Dario's solution is designed to help people adopt the healthier behaviors required to support improved clinical outcomes, which includes self-health management behaviors such as monitoring weight and blood glucose.
  • This new retrospective, quasi-randomized study examined the data from 1,932 Dario members over the course of a year.
  • The research was conducted in partnership with Integrative Pain Laboratory, the School of Public Health at the University of Haifa.

TELUS Health 2024 Drug Trends Report: Diabetes medications maintain top reimbursed expense position; ADHD drugs surge

Retrieved on: 
星期二, 四月 23, 2024
Pharmacy, Policy, Biosimilar, Health, Diabetes, Weight loss, Health Canada, Telus Health, Conference, ADHD, Depression, Prescription, Senior, Attention deficit hyperactivity disorder, Type 2 diabetes, Patient, Pharmacare, Prediabetes, Growth, Prevalence, Heart failure, Health insurance

TORONTO, April 23, 2024 /CNW/ - TELUS Health revealed today the results of its 2024 Drug Data Trends and National Benchmarks Report at its 20th annual TELUS Health Conference, running today and April 30.

Key Points: 
  • TORONTO, April 23, 2024 /CNW/ - TELUS Health revealed today the results of its 2024 Drug Data Trends and National Benchmarks Report at its 20th annual TELUS Health Conference, running today and April 30.
  • Diabetes medications remain the leading drug category for eligible private insurance claims for the second consecutive year and noteworthy spikes were observed in claims for attention deficit hyperactivity disorder (ADHD) medications, particularly among young adults.
  • Health Canada reports that over three million people in Canada, 8.9 per cent of the population, have diabetes, with a yearly prevalence growth of 3.3 per cent.
  • "Biosimilars continue to offer a significant opportunity for cost savings for private payors," adds Caroline Le Pottier, Pharmacist, TELUS Health.

Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution

Retrieved on: 
星期四, 四月 18, 2024
Diabetes, Prediabetes, Hypertension

NEW YORK, April 18, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two employers beginning in the second quarter of 2024.

Key Points: 
  • The employers, a national supply chain company and a regional education organization, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1 medication.
  • Dario combines intelligent technologies with billions of data insights gathered from a decade of consumer engagement to deliver highly personalized experiences that keep members engaged over time for optimal results.
  • Employees enrolled in Dario's cardiometabolic solution who are taking a GLP-1 medication will also have access to a tailored experience to support long-term behavior change.
  • "The trend towards integrated solutions continues to grow as employers look to reduce point solutions in favor of a single integrated solution that has a better member experience and has a lower cost of ownership when compared to managing multiple point solutions.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
星期一, 四月 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
星期一, 四月 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

Retrieved on: 
星期一, 三月 18, 2024
Diagnosis, Glucose, Histology, Adipose tissue, Arm, Glycated hemoglobin, Type 2 diabetes, Disease, Connective tissue, Steatosis, Insulin, Weight gain, Diabetes, CT1, Patient, Inflammation, SGLT2, Adiponectin, Table, MASH, MD, Liver injury, Insulin resistance, LEGEND, Fibrosis, HDL, Fatty liver disease, Empagliflozin, Safety, Euronext Paris, Phase, NASH, Hepatitis, Lipid metabolism, Prediabetes, Liver disease

Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that has been observed in some patients treated with lanifibranor.

Key Points: 
  • Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that has been observed in some patients treated with lanifibranor.
  • The treatment with lanifibranor 800mg/once daily alone or in combination with empagliflozin for 24 weeks was well tolerated, with no safety concerns reported.
  • The trial is double-blind for the placebo arm and lanifibranor (800mg daily) arm, and open-label for the combination of lanifibranor (800mg daily) and empagliflozin (10 mg daily) arm.
  • More details on these results are expected to be presented in upcoming scientific conferences and submitted for publication.

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
星期四, 三月 28, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Diagnosis, De novo, PIN, Obesity, MRI, Syndrome, Metabolism, KCH, Knowledge Organization (journal), International, National Health Service, NHS, Research, Radiology, MASH, Trial of the century, International Classification of Diseases, Hepatology, World Health Organization, Data collection, Prediabetes, NDRA, Liver, Type 2 diabetes, Liver disease, Marketing, NAFLD, Endocrinology, Video game

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.
  • Highlights from the fourth quarter of 2023 and recent weeks include:
    Installed first TAEUS system in the UK at King’s College Hospital for clinical evaluation.
  • In the third quarter of 2023, ENDRA submitted a De Novo request for its TAEUS liver system to the FDA.
  • In the fourth quarter of 2023, the FDA issued an Additional Information (AI) request to ENDRA.